Patents Expiring in May 2029
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ||||
| Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ||||
| Nalpropion | CONTRAVE | bupropion hydrochloride; naltrexone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200063-001 | Sep 10, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY | ||||
| Thea Pharma | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | ||
| Thea Pharma | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | |||
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | |||
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
